Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: ExposureDefinition: Therapeutic-dose anticoagulation with heparin

Generated Narrative: Group 179786

version: 3; Last updated: 2023-12-04 20:30:40+0000

Profile: ExposureDefinition

Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: ExposureDefinition: Therapeutic-dose anticoagulation with heparin [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179786. Revised 2023-11-30. Available at: https://fevir.net/resources/Group/179786. Computable resource at: https://fevir.net/resources/Group/179786.)

Artifact Author: Brian S. Alper:

url: https://fevir.net/resources/Group/179786

identifier: FEvIR Object Identifier/179786

name: ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin

title: ExposureDefinition: Therapeutic-dose anticoagulation with heparin

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Description: therapeutic-dose anticoagulation with heparin Note: Therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours.

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

membership: Conceptual

combinationMethod: Any of

characteristic

code: Defined by CodeableConcept

value: Therapeutic anticoagulation for 14 days (or until hospital discharge or liberation from the need for supplemental oxygen, whichever comes first) with preference for low-molecular weight heparin (LMWH), or alternative unfractionated heparin (UFH). LMWH dosed according to patient weight and creatinine clearance according to local practice and policy. For UFH, suggested target of aPTT 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels.

exclude: false

description:

ATTACC investigational arm

Timings

-ContextCodeOffset[x]Text
*Start of trial0-14Up to 14 days or until hospital discharge or recovery (defined as liberation from supplemental oxygen>24 hours, provided oxygen was required), whichever comes first.

characteristic

code: Defined by CodeableConcept

value: Low-molecular weight heparin (LMWH) dosed according to patient weight and creatinine clearance. For UFH, suggested target of anti-Xa of 0.3-0.7 IU/ml or aPTT 1.5 to 2.5 times the upper limit of normal.

exclude: false

description:

ACTIV-4a investigational arm

Timings

-ContextCodeOffset[x]Text
*Start of trial0-14Up to 14 days or until hospital discharge, whichever comes first.

characteristic

code: Defined by CodeableConcept

value: Dosed according to local hospital policy, practice, and guidelines for treatment of venous thromboembolism. Low-molecular weight heparin (LMWH) dosed according to patient weight. For UFH, suggested target for aPTT of 1.5 to 2.5 times the upper limit of normal or therapeutic anti-Xa levels.

exclude: false

description:

REMAP-CAP investigational arm

Timings

-ContextCodeOffset[x]Text
*Start of trial0-14Up to 14 days or until hospital discharge, whichever comes first.